Your browser is no longer supported. Please, upgrade your browser.
ILMN Illumina Inc. monthly Stock Chart
ILMN [NASD]
Illumina Inc.
IndexS&P 500 P/E44.74 EPS (ttm)3.10 Insider Own1.10% Shs Outstand146.40M Perf Week-7.20%
Market Cap20.31B Forward P/E32.10 EPS next Y4.32 Insider Trans-12.98% Shs Float145.06M Perf Month-16.30%
Income461.60M PEG2.57 EPS next Q0.79 Inst Own93.10% Short Float4.86% Perf Quarter-10.29%
Sales2.22B P/S9.15 EPS this Y30.80% Inst Trans2.39% Short Ratio3.22 Perf Half Y-33.51%
Book/sh12.66 P/B10.96 EPS next Y19.60% ROA12.60% Target Price184.58 Perf Year-28.51%
Cash/sh9.47 P/C14.65 EPS next 5Y17.41% ROE25.60% 52W Range130.00 - 242.37 Perf YTD-27.74%
Dividend- P/FCF36.79 EPS past 5Y28.90% ROI16.60% 52W High-42.60% Beta0.89
Dividend %- Quick Ratio3.00 Sales past 5Y19.70% Gross Margin69.80% 52W Low7.02% ATR8.75
Employees3700 Current Ratio3.40 Sales Q/Q15.40% Oper. Margin27.60% RSI (14)32.08 Volatility6.29% 5.61%
OptionableYes Debt/Eq0.59 EPS Q/Q-32.00% Profit Margin20.80% Rel Volume0.41 Prev Close138.70
ShortableYes LT Debt/Eq0.55 EarningsFeb 02 AMC Payout0.00% Avg Volume2.19M Price139.12
Recom2.40 SMA20-12.39% SMA50-19.16% SMA200-25.91% Volume882,205 Change0.30%
Feb-04-16Downgrade Canaccord Genuity Buy → Hold $205 → $160
Feb-03-16Reiterated Deutsche Bank Hold $178 → $160
Jan-07-16Reiterated Barclays Equal Weight $170 → $175
Jan-07-16Initiated Deutsche Bank Hold $192
Jan-07-16Downgrade Wells Fargo Outperform → Market Perform
Dec-21-15Reiterated Stifel Buy $175 → $215
Oct-13-15Reiterated Barclays Equal Weight $215 → $170
Oct-06-15Reiterated Stifel Buy $235 → $175
Oct-06-15Reiterated Piper Jaffray Overweight $230 → $220
Oct-06-15Reiterated Leerink Partners Mkt Perform $185 → $155
Oct-06-15Reiterated Goldman Neutral $230 → $137
Oct-06-15Downgrade Mizuho Buy → Neutral $250 → $150
Oct-01-15Downgrade Leerink Partners Outperform → Mkt Perform
Aug-27-15Initiated Cantor Fitzgerald Buy
Aug-19-15Reiterated Mizuho Buy $240 → $250
Jul-22-15Reiterated Mizuho Buy $230 → $240
Jul-22-15Reiterated Canaccord Genuity Buy $275 → $250
May-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $162 → $190
Apr-22-15Reiterated Mizuho Buy $220 → $230
Mar-10-15Initiated UBS Buy $240
Feb-11-16 04:00AM  Genomics England Enters Bioinformatics Partnership with Illumina Business Wire
Feb-10-16 09:11AM  ILLUMINA INC Files SEC form 8-K, Change in Directors or Principal Officers
09:00AM  Google's Huber to Lead Illumina Cancer-Detecting Startup Grail at Bloomberg
09:00AM  Cancer Took His Wife. Now He's CEO Of One Of The Most Audacious Cancer Startups In Years at Forbes
06:30AM  Illumina Building Long Read Application Partnerships Business Wire
06:00AM  Former Google executive to lead cancer diagnostics firm Reuters
Feb-09-16 04:00PM  STZ carries Matrix Capital in January. WDAY & DATA drag
12:19PM  5 Things Illumina Inc.'s Management Wants You to Know at Motley Fool
Feb-08-16 03:00PM  Qiagen NV Is Prepping for Growth at Motley Fool
Feb-04-16 10:36AM  Illumina, Inc. Earnings Analysis: 2015 By the Numbers
09:43AM  Illumina downgraded by Canaccord Genuity
08:55AM  Top Analyst Upgrades and Downgrades: GoPro, Illumina, Mattel, Match, Peabody, Petrobras, Wayfair, Yahoo and More at 24/7 Wall St.
08:00AM  Analysts' Actions -- GoPro, Boston Beer, Match, Whirlpool and More
Feb-03-16 03:13PM  Illumina Inc. Reports Q4 Earnings Decline at Motley Fool
03:09PM  Stock Indexes Trade Mixed, But Medicals Fall; Illumina Hits Low
01:20PM  Illumina's Earnings Miss, Revenues Beat; MiSeq Orders High
01:05PM  Illumina Brings More Pain To Battered Biotech ETFs; Gold Hits High
08:00AM  Biotechnology Stocks Technical Snapshot -- Geron, ACADIA Pharma, Alexion Pharma, and Illumina Accesswire
01:39AM  Edited Transcript of ILMN earnings conference call or presentation 2-Feb-16 10:00pm GMT
Feb-02-16 06:59PM  Yahoo Leads 5 Stocks Moving Late On Earnings Reports
05:58PM  [$$] Illumina Posts 32% Decline in Profit at The Wall Street Journal
05:00PM  Illumina Inc Earnings Call scheduled for 5:00 pm ET today
04:49PM  Illumina misses 4Q profit forecasts
04:36PM  ILLUMINA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:32PM  Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2015 Business Wire
07:07AM  Q4 2015 Illumina Inc Earnings Release - After Market Close
Feb-01-16 04:42PM  ILLUMINA INC Files SEC form 8-K, Change in Directors or Principal Officers
01:50PM  Is Illumina (ILMN) Poised to Beat Earnings Estimates in Q4?
07:10AM  Illumina Signs Multiple Biobank Deals at noodls
06:30AM  Illumina Signs Multiple Biobank Deals Business Wire
Jan-29-16 06:10PM  Adobe, Illumina, Kinder Morgan Lead This Weeks Insider Trades
06:00AM  'Mad Money' Lightning Round: I'm Buy, Buy, Buying T-Mobile US at TheStreet
Jan-28-16 07:00PM  Lightning Round: Chartists hate it, but it's a buy at CNBC -5.03%
10:49AM  Trader sees Illumina on solid ground
08:31AM  ILLUMINA INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
07:02AM  Illumina Appoints Dr. Frances Arnold to Its Board of Directors at noodls
06:30AM  Illumina Appoints Dr. Frances Arnold to Its Board of Directors Business Wire
Jan-27-16 12:02PM  3 Reasons Illumina Inc. Stock Could Fall at Motley Fool -6.06%
Jan-25-16 11:05AM  Down Syndrome Screening Is Not About Eliminating A Group Of People at Forbes
08:34AM  Why Illumina (ILMN) Might Surprise This Earnings Season
Jan-24-16 02:56PM  5 Trade ideas for Monday: Allstate, Dollar General, Fiserv, Illumina and Web.com
08:44AM  Will 2016 Be Illumina Inc.'s Best Year Yet? at Motley Fool
Jan-22-16 01:45PM  Illumina: Strategic NGS Tie-Ups Offer Hope amid Currency Woes
Jan-20-16 03:33PM  [Podcast] Why Apple's Q1 expectations and contracting multiple dont signal a short-term comeback for the stock
Jan-19-16 01:40PM  Fluidigm's Q4 Preliminary Results Fail to Woo Investors
06:30AM  Illumina to Announce Fourth Quarter and Fiscal Year 2015 Financial Results on Tuesday, February 2, 2016 Business Wire
Jan-18-16 08:59AM  Bloodied Biotech Stocks Had It Coming, But Check Out This Chart at Forbes
Jan-15-16 06:00PM  Walgreens, CVS, Illumina, Jazz Top New Insider Trades at Investor's Business Daily
05:30PM  Juno Buyout Puts Single-Cell Sequencing In Spotlight at Investor's Business Daily
Jan-14-16 12:04PM  ILLUMINA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits +6.46%
Jan-12-16 07:46PM  Biotech ETFs Snap Back After Undercutting Sept. Lows at Investor's Business Daily
01:58PM  Jeff Bezos and Bill Gates bet on blood tests for cancer at MarketWatch
08:30AM  Illumina Chases the Grail at Bloomberg
Jan-11-16 07:05PM  Celgene, Vertex, Illumina Offer Mixed Outlooks at Investor's Business Daily
06:31PM  Grail promises to detect cancer in healthy people at CNBC
04:49PM  New cancer blood test could detect disease earlier: CEO
03:44PM  We got a sneak peek at how the cancer test that Jeff Bezos and Bill Gates just invested in works
03:44PM  We got a glimpse at how the cancer test that Jeff Bezos and Bill Gates just invested in will work
02:31PM  Bio-Rad and Illumina to Co-Develop Comprehensive Solution for Single-Cell Genomics Business Wire
02:29PM  Illumina Extends Genomics Portfolio Business Wire
02:09PM  Illumina's Grail Announcement 'Underwhelmed' This Analyst
02:06PM  Why Pacific Biosciences of California Inc Is Down Big Today at Motley Fool
09:45AM  Day 1 of #JPM16: Holy Grail, rare diseases and off-the-record keynotes at bizjournals.com
09:29AM  Apple music hits milestone; Shire finally buys Baxalta; Kohl's going private?
09:15AM  A revolutionary blood test that can detect cancer at CNBC
08:45AM  Top Analyst Upgrades and Downgrades: Banco Santander, Box, GM, Illumina, JPMorgan, Noble and Many More at 24/7 Wall St.
07:58AM  Stocks eye rebound; Apple Music passes 10M mark; Teslas self-parking cars
03:48AM  Illumina Launches Firm to Pursue Gene-Based Cancer Blood Test at The Wall Street Journal
01:42AM  PRESS DIGEST- New York Times business news - Jan 11 Reuters
Jan-10-16 06:00PM  Illumina Inc Investor Call scheduled for 6:00 pm ET today
05:29PM  Illumina Forms New Company to Enable Early Cancer Detection via Blood-Based Screening Business Wire
05:00PM  [$$] Illumina Launches Firm to Pursue Gene-Based Cancer Blood Test at The Wall Street Journal
05:00PM  Illumina, partners make $100 mln bet to detect cancer via blood test
05:00PM  Illumina Starts Cancer Blood Test Firm With Bezos, Gates Backing at Bloomberg
04:53PM  Thermo Fisher: Analytics Instruments and Specialty Diagnostics
Jan-08-16 04:05PM  Illumina to Host Investor Call on Sunday, January 10, 2016 Business Wire
02:04PM  Natera, Inc. Surged 20% Higher in December. Here's Why. at Motley Fool
12:44PM  Illumina, Inc. Value Analysis (NASDAQ:ILMN) : January 8, 2016
08:12AM  Illumina, Inc. breached its 50 day moving average in a Bearish Manner : January 8, 2016
Jan-07-16 04:05PM  Illumina Files Two Patent Infringement Suits in Europe for Infringement of Patents for NIPT Business Wire -5.54%
03:44PM  Illumina Shares Lower Amid Action From Multiple Sell-Side Analysts
Jan-06-16 08:38AM  Why Pacific Biosciences of California Shares Jumped 68% in 2015 at Motley Fool
Dec-28-15 11:53AM  Notable option activity in equity names
10:48AM  Illumina traders see resistance at key level
06:30AM  Illumina to Webcast Live Presentation at the J.P. Morgan Annual Healthcare Conference Business Wire
Dec-23-15 12:00PM  Illumina (ILMN) Stock is the Chart of the Day at TheStreet
Dec-21-15 04:28PM  Apple Supplier Avago A Top Pick; BlackBerry PT Hiked at Investor's Business Daily
Dec-20-15 12:33PM  Should You Wait to Bet on Agilent Technologies?
12:22PM  Hedge Funds Love These Biotech Stocks at Insider Monkey
Dec-18-15 04:19PM  Pacific Biosciences of California's Stock Move Is Certifiable at Motley Fool
10:57AM  Hedge Funds Are Betting on These Five Capital Goods Stocks at Insider Monkey
Dec-16-15 02:10PM  Illumina-Novogene to Advance NGS Diagnostic Assay in China
Dec-14-15 04:00PM  bioMérieux and Illumina Announce the Launch of bioMérieux EpiSeq, a Revolutionary Next-Generation Sequencing Service for Epidemiological Monitoring of Bacterial Infections Business Wire
11:44AM  Novogene and Illumina to Co-Develop NGS Diagnostic System for Reproductive Health and Oncology Applications Business Wire
Dec-13-15 04:52PM  More Wild Short Interest Swings In Biotech Stocks
Dec-10-15 01:24PM  Taking ownership of your health
11:24AM  Major players in DNA mapping
06:50AM  How $199 unlocks a wealth of health data at CNBC
Dec-09-15 06:30AM  Illumina Accelerator Announces Third Funding Cycle of Genomics Startups Business Wire
01:00AM  Desktop Genetics Receives Strategic Investment from Illumina to Advance Genome Editing Software Platform Business Wire
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company's products include sequencing platforms that are based on its SBS technology, which provides researchers with various ranges of applications and the ability to sequence mammalian genomes; and array platforms consist of HiScan and iScan systems, as well as NextSeq 550 system that are array scanners for DNA and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis. It also offers various library preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping, noninvasive prenatal test, and whole-genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. It has a collaboration agreement with Merck Serono to develop a sequencing-based oncology diagnostic; Burning Rock to develop molecular diagnostics for oncology; and Memorial Sloan Kettering Cancer Center to develop of strategies to diagnose and monitor cancer, and establish ctDNA as an important marker in the study and eventual treatment of cancer. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OSTADAN OMEADEVP Ops, Products, StrategyFeb 01Sale156.731,108173,65746,476Feb 03 06:58 PM
FLATLEY JAY TChief Executive OfficerJan 26Option Exercise36.3020,000726,000453,423Jan 28 06:09 PM
FLATLEY JAY TChief Executive OfficerJan 26Sale171.7020,0003,434,082433,423Jan 28 06:09 PM
BRADBURY DANIELDirectorJan 04Option Exercise44.511,70075,66716,076Jan 04 06:33 PM
BRADBURY DANIELDirectorJan 04Sale182.801,700310,75614,376Jan 04 06:33 PM
Dadswell CharlesSr VP & General CounselDec 28Sale188.6316831,69041,830Dec 30 02:36 PM
FLATLEY JAY TChief Executive OfficerDec 22Option Exercise31.3025,000782,550458,423Dec 24 10:54 AM
FLATLEY JAY TChief Executive OfficerDec 22Sale185.3825,0004,634,560433,423Dec 24 10:54 AM
WHITFIELD ROY ADirectorDec 14Option Exercise36.293,750136,08817,398Dec 15 05:40 PM
WHITFIELD ROY ADirectorDec 14Sale175.073,750656,51313,648Dec 15 05:40 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 11Sale179.9026046,77448,293Dec 14 05:46 PM
Bianchi Paul LSr. VP, Human ResourcesDec 11Sale179.9019735,44059,827Dec 14 05:48 PM
BRADBURY DANIELDirectorDec 10Option Exercise44.511,70075,66716,076Dec 11 06:47 PM
BRADBURY DANIELDirectorDec 10Sale182.371,700310,03714,376Dec 11 06:47 PM
Dadswell CharlesSr VP & General CounselNov 27Sale180.7216930,54240,553Nov 30 05:38 PM
EPSTEIN ROBERT SDirectorNov 27Sale185.561,000185,5606,935Nov 30 05:41 PM
FLATLEY JAY TChief Executive OfficerNov 25Option Exercise27.975,000139,850428,793Nov 27 09:52 AM
FLATLEY JAY TChief Executive OfficerNov 25Sale180.005,000900,000423,793Nov 27 09:52 AM
FLATLEY JAY TChief Executive OfficerNov 24Option Exercise27.9720,000559,400443,793Nov 25 01:56 PM
FLATLEY JAY TChief Executive OfficerNov 24Sale173.2720,0003,465,342423,793Nov 25 01:56 PM
FLATLEY JAY TChief Executive OfficerNov 16Option Exercise27.9710,000279,700433,793Nov 17 08:29 PM
FLATLEY JAY TChief Executive OfficerNov 16Sale170.0010,0001,700,000423,793Nov 17 08:29 PM
Klausner RichardSr VP, Chief Medical OfficerNov 13Sale163.52730119,37023,100Nov 16 05:16 PM
BRADBURY DANIELDirectorNov 10Option Exercise44.511,70075,66716,076Nov 12 07:42 PM
BRADBURY DANIELDirectorNov 10Sale154.031,700261,84614,376Nov 12 07:42 PM
WALT DAVID RDirectorNov 10Sale154.032,000308,06436,960Nov 12 09:22 PM
Dadswell CharlesSr VP & General CounselNov 03Sale150.0015823,70040,847Nov 04 05:44 PM
FLATLEY JAY TChief Executive OfficerOct 15Option Exercise27.9710,000279,700434,996Oct 16 09:10 PM
FLATLEY JAY TChief Executive OfficerOct 15Sale150.0010,0001,500,000424,996Oct 16 09:10 PM
BRADBURY DANIELDirectorOct 07Option Exercise44.511,70075,66716,076Oct 07 07:46 PM
BRADBURY DANIELDirectorOct 07Sale145.811,700247,87814,376Oct 07 07:46 PM
WALT DAVID RDirectorSep 29Sale171.652,000343,29438,960Oct 01 05:47 PM
Dadswell CharlesSr VP & General CounselSep 28Sale173.2015727,19241,005Sep 28 07:11 PM
Klausner RichardSr VP, Chief Medical OfficerSep 28Sale173.2042373,26424,016Sep 29 04:26 PM
FLATLEY JAY TChief Executive OfficerSep 22Option Exercise27.9725,000699,250449,996Sep 23 12:42 PM
FLATLEY JAY TChief Executive OfficerSep 22Sale192.7925,0004,819,681424,996Sep 23 12:42 PM
WALT DAVID RDirectorSep 15Sale206.452,000412,89440,960Sep 17 07:39 PM
Bianchi Paul LSr. VP, Human ResourcesSep 09Sale199.321,245248,15358,519Sep 10 06:02 PM
FLATLEY JAY TChief Executive OfficerSep 08Option Exercise27.9725,000699,250449,996Sep 08 05:57 PM
EASTHAM KARINDirectorSep 08Option Exercise44.514,300191,39314,719Sep 08 06:02 PM
FLATLEY JAY TChief Executive OfficerSep 08Sale194.8725,0004,871,849424,996Sep 08 05:57 PM
EASTHAM KARINDirectorSep 08Sale195.764,300841,76810,419Sep 08 06:02 PM
WHITFIELD ROY ADirectorSep 04Option Exercise36.294,500163,30518,148Sep 09 07:56 PM
WHITFIELD ROY ADirectorSep 04Sale192.634,500866,83513,648Sep 09 07:56 PM
WALT DAVID RDirectorSep 01Sale195.082,000390,15142,960Sep 01 05:44 PM
FLATLEY JAY TChief Executive OfficerAug 27Option Exercise27.9725,000699,250449,996Aug 31 06:01 PM
Dadswell CharlesSr VP & General CounselAug 27Sale198.8116332,40641,162Aug 31 05:34 PM
FLATLEY JAY TChief Executive OfficerAug 27Sale200.1625,0005,004,125424,996Aug 31 06:01 PM
WALT DAVID RDirectorAug 18Sale206.892,000413,78544,960Aug 19 06:55 PM
BRADBURY DANIELDirectorAug 17Option Exercise75.661,700128,62216,076Aug 19 06:44 PM
BRADBURY DANIELDirectorAug 17Sale208.141,700353,84414,376Aug 19 06:44 PM
FLATLEY JAY TChief Executive OfficerAug 13Option Exercise27.9725,000699,250449,996Aug 13 06:51 PM
FLATLEY JAY TChief Executive OfficerAug 13Sale207.8525,0005,196,268424,996Aug 13 06:51 PM
Bouchard MichelChief Accounting OfficerAug 12Sale205.001,408288,64015,000Aug 13 06:03 PM
WALT DAVID RDirectorAug 11Sale208.695,4971,147,187648,840Aug 12 07:05 PM
EPSTEIN ROBERT SDirectorAug 10Option Exercise51.172,000102,3409,935Aug 12 06:46 PM
EPSTEIN ROBERT SDirectorAug 10Sale212.092,000424,1807,935Aug 12 06:46 PM
WHITFIELD ROY ADirectorAug 05Option Exercise37.244,500167,58018,148Sep 09 07:56 PM
WHITFIELD ROY ADirectorAug 05Sale215.224,500968,49013,648Sep 09 07:56 PM
WALT DAVID RDirectorAug 04Sale215.0310,0002,150,322654,337Aug 06 05:37 PM
WALT DAVID RDirectorAug 04Sale214.992,000429,98746,960Aug 06 05:37 PM
OSTADAN OMEADSr VP Product Dev & OperationsJul 29Option Exercise50.943,510178,78347,673Jul 31 05:29 PM
OSTADAN OMEADSr VP Product Dev & OperationsJul 29Sale217.933,510764,93445,673Jul 31 05:29 PM
WALT DAVID RDirectorJul 28Sale217.2910,0002,172,879664,337Jul 29 08:52 PM
Dadswell CharlesSr VP & General CounselJul 27Sale218.9216736,56041,325Jul 29 08:29 PM
BOWMAN A BLAINEDirectorJul 24Option Exercise39.143,000117,42016,615Jul 24 07:35 PM
BOWMAN A BLAINEDirectorJul 24Sale221.473,000664,40813,615Jul 24 07:35 PM
FLATLEY JAY TChief Executive OfficerJul 23Option Exercise27.9725,000699,250449,996Jul 24 07:19 PM
FLATLEY JAY TChief Executive OfficerJul 23Sale214.8725,0005,371,715424,996Jul 24 07:19 PM
WALT DAVID RDirectorJul 21Sale235.2410,0002,352,449674,337Jul 23 08:34 PM
WALT DAVID RDirectorJul 21Sale235.232,000470,46148,960Jul 23 08:34 PM
Ronaghi MostafaSr VP & CTOJul 17Sale235.001,200282,00041,856Jul 21 08:57 PM
HENRY CHRISTIAN OSr VP & Chief Commercial OfficJul 16Sale229.931,639376,85121,332Jul 17 06:29 PM
Ronaghi MostafaSr VP & CTOJul 15Sale231.581,000231,58042,056Jul 16 06:44 PM
Naclerio NicholasSr VP, Corporate DevelopmentJul 15Sale229.436,5911,512,20521,686Jul 17 05:19 PM
HENRY CHRISTIAN OSr VP & Chief Commercial OfficJul 15Sale229.483,751860,76222,971Jul 17 06:29 PM
WALT DAVID RDirectorJul 14Sale227.3910,0002,273,943684,337Jul 16 06:30 PM
Ronaghi MostafaSr VP & CTOJul 14Sale225.002,000450,00043,056Jul 16 06:44 PM
Stapley MarcSr VP & CFOJul 13Option Exercise36.302,40087,12020,298Jul 14 09:03 PM
Bouchard MichelChief Accounting OfficerJul 13Sale222.751,400311,85016,408Jul 14 08:41 PM
Stapley MarcSr VP & CFOJul 13Sale214.903,000644,70117,298Jul 14 09:03 PM
EPSTEIN ROBERT SDirectorJul 10Option Exercise51.172,000102,3409,935Jul 14 08:28 PM
EPSTEIN ROBERT SDirectorJul 10Sale219.812,000439,6207,935Jul 14 08:28 PM
OSTADAN OMEADSr VP Product Dev & OperationsJul 10Sale219.811,110243,98945,673Jul 14 08:05 PM
FLATLEY JAY TChief Executive OfficerJul 09Option Exercise27.9725,000699,250449,996Jul 10 05:10 PM
FLATLEY JAY TChief Executive OfficerJul 09Sale218.1025,0005,452,477424,996Jul 10 05:10 PM
WALT DAVID RDirectorJul 07Sale220.2210,0002,202,178694,337Jul 08 08:00 PM
WALT DAVID RDirectorJul 07Sale220.162,000440,32950,960Jul 08 08:00 PM
BRADBURY DANIELDirectorJul 06Option Exercise75.661,700128,62216,076Jul 07 02:03 PM
WHITFIELD ROY ADirectorJul 06Option Exercise39.144,500176,13018,148Jul 07 06:10 PM
BRADBURY DANIELDirectorJul 06Sale219.701,700373,48814,376Jul 07 02:03 PM
WHITFIELD ROY ADirectorJul 06Sale218.114,500981,47813,648Jul 07 06:10 PM
WALT DAVID RDirectorJun 30Sale217.6410,0002,176,449704,337Jun 30 05:56 PM
Dadswell CharlesSr VP & General CounselJun 29Sale215.6316034,50142,662Jun 29 06:30 PM
FLATLEY JAY TChief Executive OfficerJun 25Option Exercise32.6325,000815,750449,996Jun 26 04:28 PM
FLATLEY JAY TChief Executive OfficerJun 25Sale220.3425,0005,508,403424,996Jun 26 04:28 PM
BRADBURY DANIELDirectorJun 24Option Exercise75.661,700128,62216,076Jun 24 06:28 PM
HENRY CHRISTIAN OSr VP & Chief Commercial OfficJun 24Sale221.075,0841,123,90926,722Jun 24 05:25 PM
BRADBURY DANIELDirectorJun 24Sale221.231,700376,09814,376Jun 24 06:28 PM
WALT DAVID RDirectorJun 23Sale220.0910,0002,200,942714,337Jun 24 05:01 PM